
JNJ raises 2026 outlook after 6.6% Q2 sales growth led by DARZALEX and TREMFYA
Johnson & Johnson (JNJ) reported a 6.6% revenue increase to $25.3 billion in Q2 2026, driven by strong sales of key drugs DARZALEX and TREMFYA. The company raised its full-year 2026 guidance, supported by pipeline advancements including CAPLYTA's lab...

